Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Theresa Jerussi"'
Autor:
Rosandra N. Kaplan, Juan Gea-Banacloche, Terry J. Fry, Bonnie Yates, Tara N. Palmore, Seth M. Steinberg, John C Molina, Shilpa A Shahani, Lekha Mikkilineni, Crystal L. Mackall, Theresa Jerussi, James N. Kochenderfer, Nirali N. Shah, Veronique Nussenblatt, Daniel W. Lee
Publikováno v:
Blood Adv
Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to evolve, infection risks and management thereof will become increasingl
Autor:
Veronique Nussenblatt, Rachel Marchalik, Steven Z. Pavletic, Khalid Rai, Courtney D. Fitzhugh, Juan Gea-Banacloche, Richard W. Childs, Terry J. Fry, John F. Tisdale, Dimana Dimitrova, Jennifer S. Wilder, Andrea Beri, Ronald E. Gress, Ricardo J. Melendez-Munoz, Jennifer A. Kanakry, Elizabeth M. Kang, Theresa Jerussi, Christopher G. Kanakry, Matthew M. Hsieh, Sawa Ito, A. John Barrett, Daniel H. Fowler, Minoo Battiwalla, Nirali N. Shah
Human cytomegalovirus (CMV) infection and disease remains a significant cause of morbidity and mortality for hematopoietic cell transplantation (HCT) recipients. Disruption of or weak reconstitution of virus-specific cellular immune function, such as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e6d7cfb988373ba659fc8c5a92758fd
https://europepmc.org/articles/PMC6445771/
https://europepmc.org/articles/PMC6445771/
Autor:
Elizabeth M. Kang, Theresa Jerussi, Nirali N. Shah, Minoo Battiwalla, A. John Barrett, Ronald E. Gress, Matthew M. Hsieh, Ricardo J. Melendez-Munoz, Steven Z. Pavletic, Daniel H. Fowler, Rachel Marchalik, Jennifer A. Kanakry, Lauren R. Skeffington, Elizabeth M. Hellewell, Jennifer Wilder, Megan Kenyon, Courtney D. Fitzhugh, Sawa Ito, Dimana Dimitrova
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S353-S354
Latent EBV infection can lead to EBV-PTLD when proliferating, EBV+ B cells are insufficiently controlled by cellular immunity. At the National Institutes of Health (NIH), all HCT recipients are monitored weekly from day 0-100 with whole blood EBV qPC
Autor:
Rachel Marchalik, Ricardo Melendez-Munoz, Theresa Jerussi, Dimana Dimitrova, Andrea Beri, Khalid Rai, Jennifer Wilder, A. John Barrett, Minoo Battiwalla, Richard W. Childs, Courtney Fitzhugh, Daniel H. Fowler, Terry J. Fry, Ronald E. Gress, Dennis Hickstein, Matthew Hsieh, Sawa Ito, Elizabeth M. Kang, Steven Z. Pavletic, Nirali N. Shah, John F. Tisdale, Juan Gea-Banacloche, Christopher G. Kanakry, Jennifer A. Kanakry
Publikováno v:
Biology of Blood and Marrow Transplantation. 24:S377-S378
Autor:
Veronique Nussenblatt, Nirali N. Shah, Terry J. Fry, Tara N. Palmore, James N. Kochenderfer, Seth M. Steinberg, Bonnie Yates, Juan Gea-Banacloche, Theresa Jerussi, Rosandra N. Kaplan, Shilpa A Shahani, Crystal L. Mackall, Daniel W. Lee, Lekha Mikkilineni
Publikováno v:
Blood. 134:4449-4449
Background: Early data from anti-CD19 chimeric antigen receptor (CAR) T-cell trials suggest that concurrent infection can lead to poor outcomes. 1,2 The relationship between CAR T-cell mediated inflammatory responses and infections is not well-establ
Autor:
Dier Hu, Sameer S Kadri, Juan Gea-Banacloche, Harry L. Malech, Nirali N. Shah, Mark Parta, Ronald E. Gress, Kirsten M. Williams, Steven Z. Pavletic, Theresa Jerussi
Publikováno v:
Open Forum Infectious Diseases. 2
Autor:
Ross M. Fasano, Richard W. Childs, Kyoko Sugimoto, Xin Tian, Sharon Adams, Willy A. Flegel, Ewelina Mamcarz, Theresa Jerussi
Publikováno v:
British journal of haematology. 166(3)
The effects of reduced intensity conditioning (RIC) on human leucocyte antigen (HLA)-alloimmunization and platelet transfusion refractoriness (PTR) following allogeneic haematopoietic stem cell transplantation (Allo-HSCT) are unknown. We studied HLA-
Autor:
A. John Barrett, Richard W. Childs, S Soltani, Elena Cho, Theresa Jerussi, Catalina Ramos, Ramaprasad Srinivasan, Thomas E. Hughes, Lisa Cook
Publikováno v:
Blood. 122:4624-4624
Acute SR-GVHD occurs in approximately 15% of patients undergoing allogeneic hematopoietic stem cell transplant (HSCT), and is associated with a 70-90% long-term mortality rate. We previously reported that concomitant blockade of TNF-α and IL-2 pathw